October 03, 2014 (Shareholders Foundation) - An investigation on behalf of investors of NewLink Genetics Corp (NASDAQ:NLNK) shares over potential securities laws violations by NewLink Genetics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of NewLink Genetics Corp (NASDAQ:NLNK) concerning whether a series of statements by NewLink Genetics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

NewLink Genetics Corp reported that its annual Total Revenue declined from $2.08 million in 2010 to $1.09 million in 2013 and that its respective Net Loss increased from $16.21 million to $31.18 million. Shares of NewLink Genetics Corp (NASDAQ:NLNK) grew from $6.44 per share in December 2011 to as high as $46.50 per share in February 2014.

On October 1, 2014, NewLink Genetics Corp announced that Jack Henneman has been appointed Executive Vice President and Chief Financial Officer, effective immediately and that Mr. Henneman replaces Gordon H. Link, Jr., Chief Financial Officer.

Shares of NewLink Genetics Corp (NASDAQ:NLNK) declined on October 2, 2014, to as low as $21.79 per share.